Guiyang Xintian Pharmaceutical Co., Ltd. announced that it has written off inventory nearing expiry or affected by product upgrades, along with uncollectible accounts receivable, totaling 1.0926 million yuan, to be recorded in the period from January 1 to July 31, 2026. Of this, inventory write-offs amounted to 1.0327 million yuan, mainly due to near-expiry items and product upgrades, while accounts receivable write-offs totaled 59,900 yuan, arising from historical settlement differences in business transactions. The company stated that this write-off will reduce total profit for 2026 by 1.0926 million yuan, complies with the Accounting Standards for Business Enterprises, and is based on the principle of prudence, enabling a fairer reflection of the company's asset position.
Guiyang Xintian Pharmaceutical Co LtdAsset write-off of 1.0926 million yuan reduces 2026 profit.
